10-QPeriod: Q2 FY2007

DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2007

Filed July 30, 2007For Securities:DXCM

Summary

DexCom, Inc.'s (DXCM) Form 10-Q for the quarter ended June 30, 2007, reveals a company in a critical development and commercialization phase, focusing on its continuous glucose monitoring (CGM) systems. The company recently received FDA approval for its second-generation SEVENTM system, which is expected to drive future revenue. However, despite revenue growth, DexCom continues to incur significant net losses, with an accumulated deficit of $152.6 million as of the reporting period. The company's liquidity appears adequate for the next twelve months, supported by a strong cash position and short-term marketable securities, bolstered by recent financing activities including a $60 million convertible senior note issuance. Key areas of focus for investors include market acceptance of the new SEVEN system, progress in clinical trials for expanded indications (like "replacement" claim labeling and pediatric use), ongoing litigation with Abbott Diabetes Care, and the company's ability to manage its growing expenses while scaling manufacturing operations.

Key Highlights

  • 1Revenue for the three months ended June 30, 2007, increased to $863,000 from $479,000 in the prior year period, while revenue for the six months increased to $1.9 million from $494,000.
  • 2The company received FDA approval for its second-generation SEVENTM continuous glucose monitoring system on May 31, 2007, with commercialization expected in the second half of 2007.
  • 3DexCom reported a net loss of $11.3 million for the three months ended June 30, 2007, and $22.3 million for the six months ended June 30, 2007, with an accumulated deficit of $152.6 million.
  • 4As of June 30, 2007, DexCom had $25.9 million in cash and cash equivalents and $58.3 million in short-term marketable securities, totaling over $84 million in liquid assets.
  • 5In March 2007, the company issued $60 million in aggregate principal amount of 4.75% Convertible Senior Notes due 2027, using net proceeds of approximately $46.4 million after expenses and hedging costs.
  • 6Significant ongoing litigation with Abbott Diabetes Care regarding patent infringement remains a key risk factor, with reexamination proceedings underway for asserted patents.
  • 7Research and development expenses decreased year-over-year for both the three and six-month periods, while selling, general, and administrative expenses increased, partly due to executive separation costs.

Frequently Asked Questions

DexCom is a medical device company focused on continuous glucose monitoring (CGM) systems for people with diabetes. The company received FDA approval for its Short-Term Continuous Glucose Monitoring System (STS®) in March 2006 and its second-generation SEVENTM system in May 2007. Commercialization of the SEVEN system is anticipated in the second half of 2007.

While revenue has shown growth, DexCom continues to incur significant net losses, with an accumulated deficit of $152.6 million as of June 30, 2007. However, the company maintains a healthy liquidity position with over $84 million in cash, cash equivalents, and marketable securities, which management believes is sufficient to meet operating requirements for at least the next twelve months.

Key risks include market acceptance of their products, the lack of third-party reimbursement, manufacturing capacity constraints, and significant competition. A major ongoing legal challenge is a patent infringement lawsuit filed by Abbott Diabetes Care, Inc., which the company is vigorously contesting.

DexCom has primarily funded its operations through equity and debt securities, including an initial public offering in 2005, a follow-on offering in 2006, and a $60 million convertible senior note issuance in March 2007. The company anticipates continued losses and may seek additional equity or debt financing if current resources are insufficient to fund its commercialization and development activities.